Rossari Biotech (ROSSARI) Q2 26/27 earnings summary

Executive summary

• Q2 FY27 revenue reached a quarterly record of ₹697.6 crore, up 19.0% YoY; H1 revenue was ₹1,394.8 crore, up 23.5%.

• Q2 EBITDA rose 21.0% YoY to ₹87.0 crore; PAT increased 5.4% to ₹38.9 crore, with higher depreciation weighing on profit.

• Growth was broad-based, supported by healthy volumes, improved product mix, domestic momentum and expanding international presence.

Financial highlights

• Q2 gross profit was ₹220.3 crore, up 18.9% YoY; gross margin held at 31.6%, while EBITDA margin improved to 12.5% from 12.3%.

• H1 EBITDA was ₹167.6 crore, up 20.0%, with a 12.0% margin versus 12.4%; H1 PAT was ₹74.0 crore.

• Q2 EBIT was ₹57.5 crore versus ₹55.3 crore; EBIT margin was 8.2% versus 9.4%, and PAT margin was 5.6% versus 6.3%.

• Record Q2 export sales of ₹216.4 crore grew 33.8% YoY; exports were 31% of Q2 revenue and 27% of H1 revenue.

• Consolidated H1 revenue was ₹1,394.8 crore versus ₹1,129.8 crore; PAT was ₹74.0 crore versus ₹70.5 crore.

Outlook and guidance

• FY27 revenue growth is expected in the mid-teen to high-teen range; EBITDA margin guidance remains around 12%, with improvement expected from next year.

• Priorities include higher asset utilization, new-product commercialization, operating efficiency, improved product mix, customer engagement and broader international distribution.

• Exports are targeted to exceed 30% of full-year revenue; peak sales revenue from recently commissioned assets is targeted at 3x capex value by end-FY28.

• H2 is seasonally stronger for Animal Health and Nutrition, with Q3 and Q4 expected to be the division’s peak quarters.